A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Data on the effectiveness of antipsychotics in the early phase of schizophrenia are limited. The authors examined the risk of rehospitalization and drug discontinuation in a nationwide cohort of 2,588 consecutive patients hospitalized for the first time with a diagnosis of schizophrenia between 2000 and 2007 in Finland. METHOD: The authors linked national databases of hospitalization, mortality, and antipsychotic prescriptions and computed hazard ratios, adjusting for the effects of sociodemographic and clinical variables, the temporal sequence of the antipsychotics used, and the choice of the initial antipsychotic for each patient. RESULTS: Of 2,588 patients, 1,507 (58.2%) collected a prescription for an antipsychotic during the first 30 days after hospital discharge, and 1,182 (45.7%, 95% confidence interval [CI]=43.7-47.6) continued their initial treatment for 30 days or longer. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications (adjusted hazard ratio=0.36, 95% CI=0.17-0.75). Compared with oral risperidone, clozapine (adjusted hazard ratio=0.48, 95% CI=0.31-0.76) and olanzapine (adjusted hazard ratio=0.54, 95% CI=0.40-0.73) were each associated with a significantly lower rehospitalization risk. Use of any antipsychotic compared with no antipsychotic was associated with lower mortality (adjusted hazard ratio=0.45, 95% CI=0.31-0.67). CONCLUSIONS: In Finland, only a minority of patients adhere to their initial antipsychotic during the first 60 days after discharge from their first hospitalization for schizophrenia. Use of depot antipsychotics was associated with a significantly lower risk of rehospitalization than use of oral formulations of the same compounds. Among oral antipsychotics, clozapine and olanzapine were associated with more favorable outcomes. Use of any antipsychotic was associated with lower mortality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2×
“2% of patients did not regularly take medication as prescribed (8), that prescription completion rates ranged from 28% to 85% (9), and that irregular medication use rates ranged from 31% to 62% (9).”
BackgroundTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Self-citationRobinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements
Buchanan, R. W., Kreyenbuhl, J., Kelly, D. L., Noel, J. M., Boggs, D. L., Fischer, B. A., Himelhoch, S., Fang, B., Peterson, E., Aquino, P. R., et al. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp116 · Cited by 907
Compliance With Medication Regimens for Mental and Physical Disorders
Cramer, J. A., & Rosenheck, R. (1998) · Psychiatric Services · doi:10.1176/ps.49.2.196 · Cited by 725
Adverse Effects of Atypical Antipsychotics: Differential Risk and Clinical Implications
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 456
Self-citationMedication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Research works printed but not linked: 4
- National Institute for Health and Clinical Excellence (NICE), 2009, Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)
- Young JL, 1986, Bull Am Acad Psychiatry Law, 14, 105
- Young JL, 1999, J Am Acad Psychiatry Law, 27, 426
- 10.1176/ps.2007.58.4.482 · doi:10.1176/ps.2007.58.4.482 · Paper page
Cited by
Items 101–200 of 618
Kishi, T., Matsunaga, S., & Iwata, N. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw043 · Cited by 60
Titus-Lay, E. N., Ansara, E. D., Isaacs, A. N., & Ott, C. (2018) · Mental Health Clinician · doi:10.9740/mhc.2018.03.056 · Cited by 47
Kane, J. M., Sanchez, R., Zhao, J. L., Duca, A. R., Johnson, B. R., McQuade, R. D., Eramo, A., Baker, R. A., & Peters-Strickland, T. S. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2013.804411 · Cited by 54
Improving Treatment Adherence in Your Patients with Schizophrenia: The STAY Initiative
Cañas, F., Alptekın, K., Azorin, J. M., Dubois, V., Emsley, R. A., García, A. G., Gorwood, P. A. P. M., Haddad, P. M., Naber, D., Olivares, J. M., et al. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-012-0047-8 · Cited by 65
Self-citationTaylor, D. M., & Olofinjana, O. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000028 · Cited by 49
Kane, J. M., Zhao, C. Y., Johnson, B. R., Baker, R. A., Eramo, A., McQuade, R. D., Duca, A. R., Sanchez, R., & Peters-Strickland, T. S. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.979936 · Cited by 53
Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes
Mayfield, K., Siskind, D., Winckel, K., Russell, A. W., Kisely, S., Smith, G., & Hollingworth, S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881115625496 · Cited by 49
Shirley, M., & Perry, C. M. (2014) · Drugs · doi:10.1007/s40265-014-0231-7 · Cited by 57
Mohr, P., Knytl, P., Voráčková, V., Bravermanová, A., & Melicher, T. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12997 · Cited by 55
Hard, M. L., Mills, R. J., Sadler, B. M., Wehr, A. Y., Weiden, P. J., & von Moltke, L. (2017) · CNS Drugs · doi:10.1007/s40263-017-0447-7 · Cited by 44
Harlin, M., Yildirim, M., Such, P., Madera‐McDonough, J., Jan, M., Jin, N., Watkin, S., & Larsen, F. (2023) · CNS Drugs · doi:10.1007/s40263-023-00996-8 · Cited by 50
Osser, D. N., Roudsari, M. J., & Manschreck, T. C. (2013) · Harvard Review of Psychiatry · doi:10.1097/hrp.0b013e31827fd915 · Cited by 49
Fagiolini, A. M., Rocca, P., Giorgi, S. D., Spina, E., Amodeo, G., & Amore, M. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.11.044 · Cited by 52
Milz, R., Benson, C. J., Knight, K., Antunes, J., Najarian, D. M., Rengel, P. M. L., Wang, S., Richarz, U., Gopal, S., & Kane, J. M. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s395383 · Cited by 54
Boyer, L., Falissard, B., Nuss, P., Collin, C., Duret, S., Rabbani, M., Chefdebien, I. D., Tonelli, I., Llorca, P., & Fond, G. B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02175-z · Cited by 54
Turncliff, R. Z., Hard, M., Du, Y., Risinger, R. C., & Ehrich, E. W. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.021 · Cited by 45
Lorenzo, R. D., Ferri, P., Cameli, M., Rovesti, S., & Piemonte, C. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s189245 · Cited by 48
Drake, R. J., Nordentoft, M., Haddock, G., Arango, C., Fleischhacker, W. W., Glenthøj, B., Leboyer, M., Leucht, S., Leweke, M., McGuire, P., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv015 · Cited by 42
Prevalence of treatment-resistant psychoses in the community: A naturalistic study
Beck, K., McCutcheon, R. A., Stephenson, L., Schilderman, M., Patel, N., Ramsay, R., & Howes, O. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855995 · Cited by 43
Long-acting injectable antipsychotics: what, when, and how
Citrome, L. (2021) · CNS Spectrums · doi:10.1017/s1092852921000249 · Cited by 46
Gentile, S. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1313 · Cited by 46
Brain, C., Sameby, B., Allerby, K., Quinlan, P. S., Joas, E., Lindström, E., Burns, T., & Wærn, M. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.10.016 · Cited by 55
Godman, B., Petzold, M., Bennett, K., Bennie, M., Bucsics, A., Finlayson, A. E. T., Martin, A. A., Persson, M., Piessnegger, J., Raschi, E., et al. (2014) · BMC Medicine · doi:10.1186/1741-7015-12-98 · Cited by 40
Arango, C., Baeza, I., Bernardo, M., Cañas, F., de Dios, C., Díaz‐Marsá, M., García‐Portilla, M. P., Gutiérrez-Rojas, L., Olivares, J. M., Rico‐Villademoros, F., et al. (2018) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2018.03.006 · Cited by 53
Attitudes of European physicians towards the use of long-acting injectable antipsychotics
Patel, M. X., Bent‐Ennakhil, N., Sapin, C., di Nicola, S., Loze, J.-Y., Nylander, A.-G., & Heres, S. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02530-2 · Cited by 44
Self-citationBallenger, J. C. (2012) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/j.ypsy.2011.10.012 · Cited by 40
Olivares, J. M., Alptekın, K., Azorin, J., Cañas, Dubois, Emsley, R., Gorwood, P. A. P. M., Haddad, P. M., Naber, Papageorgiou, et al. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s37534 · Cited by 44
Self-citationBioque, M., LLerena, A., Cabrera, B., Mezquida, G., Lobo, A., González-Pinto, A. M., Díaz‐Caneja, C. M., Corripio, I., Aguilar, E. J., Bulbena, A., et al. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv121 · Cited by 42
Taylor, D. M., Sparshatt, A., O’Hagan, M., & Dzahini, O. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.04.009 · Cited by 42
Ljungdalh, P. S. (2017) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2017.08.001 · Cited by 39
Stip, É., & Lachaîne, J. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125318782694 · Cited by 40
Abdel‐Baki, A., Thibault, D., Medrano, S., Stip, É., Ladouceur, M., Tahir, M. R., & Potvin, S. (2019) · Early Intervention in Psychiatry · doi:10.1111/eip.12826 · Cited by 47
Schreiner, A., Bergmans, P., Chérubin, P., Keim, S., Rancāns, E., Bez, Y., Parellada, E., Carpiniello, B., Vidailhet, P., & Hargarter, L. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.014 · Cited by 40
Kozma, C. M., Slaton, T. L., Dirani, R. D., Fastenau, J. M., Gopal, S., & Hough, D. W. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.595000 · Cited by 38
Suzuki, T. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1115479 · Cited by 41
Lin, C., Chen, F.-C., Chan, H., & Hsu, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz035 · Cited by 40
Why are long-acting injectable antipsychotics still underused?
Bosanac, P., & Castle, D. J. (2015) · BJPsych Advances · doi:10.1192/apt.bp.114.013565 · Cited by 36
Komatsu, H., Sekine, Y., Okamura, N., Kanahara, N., Okita, K., Matsubara, S., Hirata, T., Komiyama, T., Watanabe, H., Minabe, Y., et al. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.08.007 · Cited by 37
ANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 41
Munday, J., Greene, M., Chang, E. Y., Hartry, A., Yan, T., & Broder, M. S. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1571295 · Cited by 40
Current and emerging long-acting antipsychotics for the treatment of schizophrenia
de Filippis, R., Fazio, P. D., Gaetano, R., Steardo, L., Cedro, C., Bruno, A., Zoccali, R. A., & Muscatello, M. R. A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1910674 · Cited by 47
Citrome, L. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1121809 · Cited by 37
Okoli, C. T. C., Kappi, A. A., Wang, T., Makowski, A., & Cooley, A. T. (2021) · International Journal of Mental Health Nursing · doi:10.1111/inm.12964 · Cited by 37
Taipale, H. T., Tanskanen, A., Howes, O. D., Correll, C. U., Kane, J. M., & Tiihonen, J. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00366-3 · Cited by 43
Self-citationMarkowitz, M., Fu, D., Levitan, B. S., Gopal, S., Turkoz, I., & Alphs, L. D. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-22 · Cited by 38
The treatment of schizophrenia: Can we raise the standard of care?
Catts, S. V., & O’Toole, B. I. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416672725 · Cited by 35
Baandrup, L., Rasmussen, J. Ø., Klokker, L., Austin, S. F., Bjørnshave, T., Bliksted, V., Fink‐Jensen, A., Fohlmann, A., Hansen, J. P., Nielsen, M. K., et al. (2015) · Nordic Journal of Psychiatry · doi:10.3109/08039488.2015.1074285 · Cited by 43
Aymerich, C., de Pablo, G. S., Pacho, M., Pérez-Rodríguez, V., Bilbao, A., Andrés, L. G., Pedruzo, B., Castillo-Sintes, I., Aranguren, N., Fusar‐Poli, P., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02694-3 · Cited by 44
Montgomery, W. S., Liu, Ascher‐Svanum, H., Xue, Treuer, T., & Stensland, M. D. (2013) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s44325 · Cited by 39
Bitter, I., Katona, L., Zámbori, J., Takács, P., Fehér, L., Diels, J., Bacskai, M., Láng, Z., Gyáni, G., & Czobor, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.02.003 · Cited by 34
Lee, S. Y., Kim, K. H., Kim, T., Kim, S. M., Kim, J., Han, C., Song, J. Y., & Paik, J. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.4.425 · Cited by 41
Verdoux, H., Pambrun, É., Tournier, M., Bezin, J., & Pariente, A. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.09.014 · Cited by 34
Chiliza, B., Asmal, L., Oosthuizen, P., van Niekerk, E., Erasmus, R. T., Kidd, M., Malhotra, A. K., & Emsley, R. A. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2014.11.013 · Cited by 44
Bossie, C. A., Alphs, L. D., & Correll, C. U. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000082 · Cited by 33
Højlund, M., & Correll, C. U. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2228686 · Cited by 40
Kroken, R. A., Kjelby, E., Wentzel‐Larsen, T., Mellesdal, L., Jørgensen, H. A., & Johnsen, E. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314545614 · Cited by 33
Cheung, S., Hamuro, Y., Mahlich, J., Nakahara, T., Sruamsiri, R., & Tsukazawa, S. (2017) · Clinical Drug Investigation · doi:10.1007/s40261-017-0517-0 · Cited by 33
Olagunju, A. T., Clark, S. R., & Baune, B. T. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419837358 · Cited by 37
Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia
Qubad, M., & Bittner, R. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231158152 · Cited by 35
Horvitz-Lennon, M. V., Volya, R., Donohue, J. M., Lave, J. R., Stein, B. D., & Normand, S. T. (2014) · Health Services Research · doi:10.1111/1475-6773.12162 · Cited by 38
Koppel, J. L., Jimenez, H. T., Adrien, L. R., GREENWALD, B. S., Marambaud, P., Cinamon, E., & Davies, P. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.05.003 · Cited by 34
Citrome, L. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1371014 · Cited by 35
A review on schizophrenia and relapse—a quest for user‐friendly psychopharmacotherapy
Suzuki, T., Uchida, H., Takeuchi, H., Tsuboi, T., Hirano, J., & Mimura, M. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2421 · Cited by 39
Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
Zeidler, J., Mahlich, J., Greiner, W., & Heres, S. (2013) · Applied Health Economics and Health Policy · doi:10.1007/s40258-013-0050-0 · Cited by 32
MacEwan, J. P., Kamat, S., Duffy, R. A., Seabury, S. A., Chou, J. W., Legacy, S. N., Hartry, A., Eramo, A., & Karson, C. N. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500455 · Cited by 37
Vega, D., Acosta, F. J., & Saavedra, P. (2021) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2021.152240 · Cited by 49
Rocca, P., Montemagni, C., & Frieri, T. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s88632 · Cited by 40
Antipsychotic use among persons with schizophrenia in Sweden and Finland, trends and differences
Taipale, H. T., Puranen, A., Mittendorfer‐Rutz, E., Tiihonen, J., Tanskanen, A. J., Červenka, S., & Lähteenvuo, M. (2020) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2020.1854853 · Cited by 38
Self-citationReal-world clinical and cost-effectiveness of community clozapine initiation: mirror cohort study
Butler, E., Pillinger, T., Brown, K., Borgan, F., Bowen, A. M., Beck, K., D’Ambrosio, E., Donaldson, L., Jauhar, S., Kaar, S. J., et al. (2022) · The British Journal of Psychiatry · doi:10.1192/bjp.2022.47 · Cited by 31
Brain, C., Sameby, B., Allerby, K., Lindström, E., Eberhard, J., Burns, T., & Wærn, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.11.013 · Cited by 35
Understanding depot antipsychotics: an illustrated guide to kinetics
Meyer, J. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000783 · Cited by 31
Hargarter, L., Bergmans, P., Chérubin, P., Keim, S., Conca, A., Serrano‐Blanco, A., Bitter, I., Bilanakis, N., & Schreiner, A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1174692 · Cited by 32
Lachaîne, J., Lapierre, M.-È., Abdalla, N., Rouleau, A., & Stip, É. (2015) · Europe PMC (PubMed Central) · Cited by 31
Verdoux, H., Pambrun, É., Tournier, M., Bezin, J., & Pariente, A. (2017) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12722 · Cited by 36
Malla, A., Chue, P., Jordan, G., Stip, E., Koczerginski, D., Milliken, H., Joseph, A., Williams, R., Adams, B., Manchanda, R., et al. (2016) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.mach.061213 · Cited by 30
Schöttle, D., Janetzky, W., Luedecke, D., Beck, E., Correll, C. U., & Wiedemann, K. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1946-x · Cited by 32
Koola, M. M., Wehring, H. J., & Kelly, D. L. (2012) · Journal of Dual Diagnosis · doi:10.1080/15504263.2012.647345 · Cited by 34
Stip, É., Vincent, P. D., Sablier, J., Guevremont, C., Zhornitsky, S., & Tranulis, C. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00100 · Cited by 37
Lo, T. L., Warden, M., He, Y., Si, T., Kalyanasundaram, S., Thirunavukarasu, M., Amir, N., Hatim, A., Bautista, T. C., Lee, C., et al. (2016) · Asia-Pacific Psychiatry · doi:10.1111/appy.12234 · Cited by 30
Is paliperidone palmitate more effective than other long-acting injectable antipsychotics?
Patel, R., Chesney, E., Taylor, M. J., Taylor, D. M., & McGuire, P. K. (2017) · Psychological Medicine · doi:10.1017/s0033291717003051 · Cited by 32
Self-citationSchoretsanitis, G., de León, J., Haen, E., Stegmann, B., Hiemke, C., Gründer, G., & Paulzen, M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.11.009 · Cited by 30
Keinänen, J., Mantere, O., Kieseppä, T., Mäntylä, T. J. S., Torniainen, M., Lindgren, M., Sundvall, J., & Suvisaari, J. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.11.002 · Cited by 31
Decuypere, F., Sermon, J., Geerts, P., Denee, T. R., Vos, C. D., Malfait, B., Lamotte, M., & Mulder, C. L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179049 · Cited by 32
Increased use of antipsychotic long-acting injections with community treatment orders
Patel, M. X., Matonhodze, J., Baig, M. K., Gilleen, J., Boydell, J. E., Holloway, F. A., Taylor, D. M., SZMUKLER, G. I., Lambert, T. J. R., & David, A. S. (2011) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125311407960 · Cited by 29
Self-citationEffectiveness of long-acting injectable antipsychotics: a clinical perspective
Castillo, E. G., & Stroup, T. S. (2015) · Evidence Based Mental Health · doi:10.1136/eb-2015-102086 · Cited by 28
Takács, P., Czobor, P., Fehér, L., Gimesi-Országh, J., Fadgyas‐Freyler, P., Bacskai, M., Rakonczai, P., Borsi, A., Hegyi, R., Németh, T., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0218071 · Cited by 29
Improving adherence to pharmacological treatment for schizophrenia: a systematic assessment
Curto, M., Fazio, F., Ulivieri, M., Navari, S., Lionetto, L., & Baldessarini, R. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1882996 · Cited by 33
Whale, R., Pereira, M., Cuthbert, S., & Fialho, R. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000385 · Cited by 28
Chiliza, B., Ojagbemi, A., Esan, O., Asmal, L., Oosthuizen, P. P., Kidd, M., Gureje, O., & Emsley, R. A. (2014) · Early Intervention in Psychiatry · doi:10.1111/eip.12141 · Cited by 31
Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
Mahlich, J., Kuwabara, H., & Yoshimichi, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s81677 · Cited by 33
Effectiveness of antipsychotics used in first-episode psychosis: a naturalistic cohort study
Whale, R., Harris, M., Kavanagh, G., Wickramasinghe, V., Jones, C. I., Marwaha, S., Jethwa, K. D., Ayadurai, N., & Thompson, A. D. (2016) · BJPsych Open · doi:10.1192/bjpo.bp.116.002766 · Cited by 29
Pesa, J. A., Doshi, D., Wang, L., Yüce, H., & Baser, O. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1278202 · Cited by 30
Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
Brasso, C., Bellino, S., Bozzatello, P., Montemagni, C., & Rocca, P. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150568 · Cited by 27
Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs
Santos-Casado, M., & García-Avello, A. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001041 · Cited by 30
Barbui, C., Bertolini, F., Bartoli, F., Calandra, C., Callegari, C., Carrà, G., D’Agostino, A., Lucii, C., Martinotti, G., Mastromo, D., et al. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320978102 · Cited by 29
Fu, A. Z., Pesa, J. A., Lakey, S. L., & Benson, C. J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03895-2 · Cited by 30
Samtani, C., Sliwa, Fu, Turkoz, & Alphs, L. D. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s32581 · Cited by 27
Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
Berardis, D. D., Marini, S., Carano, A., Lang, A., Cavuto, M., Piersanti, M., Fornaro, M., Perna, G., Valchera, A., Mazza, M., et al. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990056 · Cited by 31
Stürup, A. E., Hjorthøj, C. R., Jensen, H., Melau, M., Davy, J. W., Nordentoft, M., & Albert, N. (2023) · Early Intervention in Psychiatry · doi:10.1111/eip.13389 · Cited by 27
Alphs, L. D., Bossie, Sliwa, Fu, A, M., & Hulihan (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36438 · Cited by 28
Metadata
- Authors
- Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P.
- Affiliations
- NHS Lothian (GB)
- Venue
- American Journal of Psychiatry
- Published
- 2011-06
- Volume
- 168
- Issue
- 6
- Pages
- 603-609
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2160096204
- Cited by
- 619
- References
- 28
- Citations by year
- 2026: 21 · 2025: 30 · 2024: 21 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 32 · 2019: 42 · 2018: 51 · 2017: 55 · 2016: 39 · 2015: 52 · 2014: 42 · 2013: 61 · 2012: 44
- FWCI
- 34.80
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Clinical Psychology › Psychiatric care and mental health services
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- schizophrenia, antipsychotic drugs, long-acting injectable antipsychotics, oral antipsychotics, hospital readmission, treatment discontinuation, clozapine, olanzapine, risperidone, mortality, medication adherence, first hospitalization
- MeSH terms
- Administration, Oral, Adolescent, Adult, Delayed-Action Preparations, Drug Implants, Finland, Hospitalization, Humans, Injections, Middle Aged, Patient Readmission, Schizophrenia, Antipsychotic Agents, Cohort Studies, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.